# OnCo record nct06349980 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06349980/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06349980", "NCT06349980" ;
  schema:name "A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients."@en ;
  schema:description "A phase 2 trial of Serplulimab in hepatocellular carcinoma, run by Shanghai Henlius Biotech, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06349980/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06349980> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2024-08-05" ;
  onco:cancers <https://onco.cc/cancers/hcc/>, <https://onco.cc/cancers/hcc-advanced/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/serplulimab/> ;
  onco:companies <https://onco.cc/companies/henlius/> .